These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 2260966)

  • 41. Amplification and co-regulators of androgen receptor gene in prostate cancer.
    Golias Ch; Iliadis I; Peschos D; Charalabopoulos K
    Exp Oncol; 2009 Mar; 31(1):3-8. PubMed ID: 19300409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
    Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.
    Steketee K; Timmerman L; Ziel-van der Made AC; Doesburg P; Brinkmann AO; Trapman J
    Int J Cancer; 2002 Jul; 100(3):309-17. PubMed ID: 12115546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells.
    Chang GT; Steenbeek M; Schippers E; Blok LJ; van Weerden WM; van Alewijk DC; Eussen BH; van Steenbrugge GJ; Brinkmann AO
    J Natl Cancer Inst; 2000 Sep; 92(17):1414-21. PubMed ID: 10974077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myosin VI is a modulator of androgen-dependent gene expression.
    Loikkanen I; Toljamo K; Hirvikoski P; Väisänen T; Paavonen TK; Vaarala MH
    Oncol Rep; 2009 Nov; 22(5):991-5. PubMed ID: 19787211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgen regulation of the human ornithine decarboxylase promoter in prostate cancer cells.
    Bai G; Kasper S; Matusik RJ; Rennie PS; Moshier JA; Krongrad A
    J Androl; 1998; 19(2):127-35. PubMed ID: 9570735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD; Gleave ME
    Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of the deoxyribonucleic acid-binding site of a regulatory protein involved in prostate-specific and androgen receptor-dependent gene expression.
    Patrikainen L; Shan J; Porvari K; Vihko P
    Endocrinology; 1999 May; 140(5):2063-70. PubMed ID: 10218955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgen receptor alterations in patients with disturbances in male sexual development and in prostatic carcinoma.
    Klocker H; Neuschmid-Kaspar F; Culig Z; Cato AC; Hobisch A; Eberle J; Cronauer MV; Hittmair A; Radmayr C; Uberreiter S
    Urol Int; 1995; 54(1):2-5. PubMed ID: 7770997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.
    Truica CI; Byers S; Gelmann EP
    Cancer Res; 2000 Sep; 60(17):4709-13. PubMed ID: 10987273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
    Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
    Krishnan AV; Zhao XY; Swami S; Brive L; Peehl DM; Ely KR; Feldman D
    Endocrinology; 2002 May; 143(5):1889-900. PubMed ID: 11956172
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human androgen insensitivity due to point mutations encoding amino acid substitutions in the androgen receptor steroid-binding domain.
    Murono K; Mendonca BB; Arnhold IJ; Rigon AC; Migeon CJ; Brown TR
    Hum Mutat; 1995; 6(2):152-62. PubMed ID: 7581399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment.
    Thin TH; Wang L; Kim E; Collins LL; Basavappa R; Chang C
    J Biol Chem; 2003 Feb; 278(9):7699-708. PubMed ID: 12499384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Mutations of the androgen receptor gene a possible role in prostate cancer].
    Mowszowicz I; Mestayer C
    Bull Cancer; 1997 Feb; 84(2):183-8. PubMed ID: 9180843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation.
    Kokontis J; Takakura K; Hay N; Liao S
    Cancer Res; 1994 Mar; 54(6):1566-73. PubMed ID: 7511045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-->Arg) that results in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels.
    Choong CS; Sturm MJ; Strophair JA; McCulloch RK; Tilley WD; Leedman PJ; Hurley DM
    J Clin Endocrinol Metab; 1996 Jan; 81(1):236-43. PubMed ID: 8550758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.